Advances in ovarian cancer therapy

Epithelial ovarian cancer is typically diagnosed at an advanced stage. Current state-of-the-art surgery and chemotherapy result in the high incidence of complete remissions; however, the recurrence rate is also high. For most patients, the disease eventually becomes a continuum of symptom-free perio...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Cancer chemotherapy and pharmacology Ročník 81; číslo 1; s. 17 - 38
Hlavní autoři:	Cortez, Alexander J., Tudrej, Patrycja, Kujawa, Katarzyna A., Lisowska, Katarzyna M.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Berlin/Heidelberg Springer Berlin Heidelberg 01.01.2018 Springer Nature B.V
Témata:	Angiogenesis Cancer Research Cancer therapies cancer therapy Chemotherapy chronic diseases Chronic illnesses Clinical trials cost effectiveness Drug development drug therapy epithelium folate receptors Folic acid immunotherapy Medicine Medicine & Public Health Oncology Ovarian cancer ovarian neoplasms Pharmacology/Toxicology Poly(ADP-ribose) polymerase Review Review Article Ribose Surgery Clinical trials Biological drugs Targeted therapy Ovarian cancer
ISSN:	0344-5704, 1432-0843, 1432-0843
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	Epithelial ovarian cancer is typically diagnosed at an advanced stage. Current state-of-the-art surgery and chemotherapy result in the high incidence of complete remissions; however, the recurrence rate is also high. For most patients, the disease eventually becomes a continuum of symptom-free periods and recurrence episodes. Different targeted treatment approaches and biological drugs, currently under development, bring the promise of turning ovarian cancer into a manageable chronic disease. In this review, we discuss the current standard in the therapy for ovarian cancer, major recent studies on the new variants of conventional therapies, and new therapeutic approaches, recently approved and/or in clinical trials. The latter include anti-angiogenic therapies, polyADP-ribose polymerase (PARP) inhibitors, inhibitors of growth factor signaling, or folate receptor inhibitors, as well as several immunotherapeutic approaches. We also discuss cost-effectiveness of some novel therapies and the issue of better selection of patients for personalized treatment.
Bibliografie:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Literature Review-3 ObjectType-Review-3 content type line 23
ISSN:	0344-5704 1432-0843 1432-0843
DOI:	10.1007/s00280-017-3501-8